Join us for an insightful podcast episode exploring the treatment of intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today.
Expert in the field, Dr. Marco Moschini, delves into this “risk-adapted treatment” approach, where patients are assigned to a particular risk group based on patient and tumor-related factors, also taking into account prior treatment history and the timing of recurrences.
Topics discussed include:
- Current confusion about the clinical heterogeneity within the intermediate-risk patient goup
- The best way to select adequate intravesical therapy for this group
- The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy in general
To view the Mitomycin medac abbreviated product information please click here.
* References:
- Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208.
- European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/
- Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683.
- Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695.
- Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline
- Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.
